Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
Microsatellite-stable (MSS) colorectal cancer (CRC) has shown poor response to checkpoint blockade immunotherapy. Here, the authors show that the combination of oxaliplatin with anti-PDL1 mAb is specifically efficient in the treatment of MSS CRC.
Guardado en:
Autores principales: | Wantong Song, Limei Shen, Ying Wang, Qi Liu, Tyler J. Goodwin, Jingjing Li, Olekasandra Dorosheva, Tianzhou Liu, Rihe Liu, Leaf Huang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0515a6d971844b1e8f9a10f726dac7a6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade
por: Guido Kroemer, et al.
Publicado: (2021) -
Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
por: Hongji Zhang, et al.
Publicado: (2021) -
Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Chengming Liu, et al.
Publicado: (2021) -
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
por: Jianqin Lu, et al.
Publicado: (2017) -
Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors
por: Hua Wang, et al.
Publicado: (2020)